Hypoxia represents the prevailing adverse occurrence during the sedation of patients undergoing fiberoptic bronchoscopy with propofol. A recent innovation in this domain is the COMBO Endoscopy Oropharyngeal Airway-a multifaceted device that encompasses capnography monitoring, bite block , oxygenation support, and oropharyngeal airway management. This device has been purposefully designed to cater to the unique requirements of endoscopic procedures. The principal objective of our randomized study is to assess the efficacy and safety of the COMBO Endoscopy Oropharyngeal Airway reduce the incidence of hypoxia on patients undergoing fiberoptic bronchoscopy under propofol sedation.

Inclusion Criteria:

• Age 18≤ Age ≤70.·Patients undergoing fiberoptic bronchoscopy.
• Patients have signed the informed consent form.
• The ASA classification ranges from I to II.
• The estimated duration of the procedure does not exceed 45 minutes.

Exclusion Criteria:

• Patients with contraindications to oropharyngeal airway ventilation, such as coagulation disorders, predisposition to oral/nasal bleeding, mucosal damage, or anatomical obstructions hindering oropharyngeal airway placement.
• Patients diagnosed with acute exacerbation of chronic obstructive pulmonary disease (COPD) or those currently suffering from other acute/chronic pulmonary conditions requiring long-term or intermittent oxygen therapy.
• Patients with preoperative SpO₂ < 95% while breathing air.
• Patients with BMI < 18.5 or BMI > 30.
• Patients with upper respiratory tract infections (oral, nasal, or pharyngeal).
• Patients at risk of aspiration.
• Patients with fever (core temperature > 37.5°C).
• Patients with severe cardiac insufficiency (< 4 METs).
• Patients with severe renal insufficiency requiring preoperative dialysis.
• Patients with a confirmed diagnosis of hepatic insufficiency.
• Patients with increased intracranial pressure.
• Patients with hypersensitivity to sedatives like propofol or medical equipment such as adhesive tape.
• Patients with a history of drug abuse and/or alcoholism within the two years preceding the commencement of the screening period (defined as drinking more than three standard alcoholic beverages daily, roughly equivalent to 10g of alcohol or 50g of Chinese Baijiu).
• Patients with a history of mental and neurological disorders, including but not limited to depression, severe central nervous system depression, Parkinson's disease, basal ganglia lesions, schizophrenia, epilepsy, Alzheimer's disease, and myasthenia gravis.
• Patients currently participating in other clinical trials.
• Patients deemed ineligible for participation in this clinical trial by the researchers.